SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

__________________



FORM 8-K



CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported):  May 15, 2017



THE FEMALE HEALTH COMPANY

(Exact name of registrant as specified in its charter)



Wisconsin

(State or other jurisdiction of incorporation)



1-13602

 

39-1144397

(Commission File Number)

 

(I.R.S. Employer I.D. Number)



4400 Biscayne Boulevard

Suite 888

Miami, Florida

 

 

 

33137

(Address of Principal Executive Offices)

 

(Zip Code)



312-595-9123

(Registrant's telephone number, including area code)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).



Emerging growth company  



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  




 



Section 1 – Registrant's Business and Operations

Item 1.01    Entry into a Material Definitive Agreement.

On May 15, 2017, The Female Health Company (the "Company") entered into a Fourth Amendment, dated effective as of March 30, 2017 (the "Amendment"), to its Credit Agreement (the "Credit Agreement") with BMO Harris Bank N.A. (the "Bank").  The Amendment makes changes to the financial covenants in the Credit Agreement, including the tangible net worth covenant and the definition of "EBITDA" used in the total leverage ratio covenant.



The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by the full text of the Amendment, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.



Section 9 - Financial Statements and Exhibits



Item 9.01.Financial Statements and Exhibits.



(d)Exhibits



99.1 ‑ Fourth Amendment to Credit Agreement, effective as of March 30, 2017, among The Female Health Company, Aspen Park Pharmaceuticals, Inc., Badger Acquisition Sub, Inc. and BMO Harris Bank N.A.



2


 

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







 



THE FEMALE HEALTH COMPANY

Date: May 19, 2017

 



/s/ Daniel Haines



Daniel Haines, Chief Financial Officer





3